



PATENT
Attorney Docket No. 11707.00
Express Mail No. EV 156 913 267 US

#16/C
11/21/02
Z. M. M. M.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Mathew et al.
Serial No. 09/475,365
Filed: December 30, 1999
For: LLT USES THEREOF IN IMMUNE
SYSTEM MODULATION

Examiner: RUIXIANG, LI
Art Unit: 1646

RECEIVED
NOV 08 2002

TECH CENTER 1600/2900

AMENDMENT AND RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Official Action mailed May 6, 2002, Applicants respectfully request entry of the following amendment and consideration of the following remarks. Applicants note that the period for responding to this Office Action is being extended for three months from August 6, 2002 until November 6, 2002 by the enclosed petition under 37 CFR 1.36(a).

In the Specification

Please replace the sentence beginning at page 7, line 21, with the following rewritten sentence:

The expressed sequence tag (EST) database at GenBank was searched with the TblastN program against a consensus sequence of human (CD69, CD94, and NKG2's) and mouse (Ly-49's) C-type lectin receptors (Boguski et al. 1993, 1995).

In the Claims

Please amend claims as follows:

1. (Amended) A polypeptide molecule having an amino acid sequence derived from a lectin-like transcript 1 receptor wherein the receptor has a transmembrane domain near the N-terminus of the polypeptide, and having a length of about 185 to about 205 amino acid residues,

C2